Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motexafin Gadolinium in Refractory/Relapsed CLL/SLL
NCT00290004Phase 2Completed
- Sponsor
- Pharmacyclics
- Start
- Nov 2005
- Primary completion
- Feb 2007
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of motexafin gadolinium in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Pharmacyclics. Started Nov 2005; status: completed.
02
Drugs
motexafin gadolinium
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT00290004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00290004.